ADA 2025
This is the logo of the provider
ADA 2025 20 - 23 June 2025

Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD: Data from the FLOW Trial

Authors :

Johannes F. E. Mann1,2; Katherine R. Tuttle3,4; Richard E. Pratley5; Kenneth W. Mahaffey6; Mustafa Arici7; Nicolas Belmar8; Karen Bonefeld8; Gil Chernin9; Ricardo Correa-Rotter10; Pieter Gillard11; Samy Hadjadj12; Thomas Idorn8; Linong Ji13; Soo Kun Lim14; Martin Linder8; Roland Schmieder15; Minara Shamkhalova16; Apiradee Sriwijitkamol17; Vlado Perkovic18; Peter Rossing19
Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Download poster (.pdf)
Keywords
Chronic Kidney Disease
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)